M&A Deal Summary |
|
---|---|
Date | 2022-03-28 |
Target | Acacia Pharma |
Sector | Life Science |
Buyer(s) | Eagle Pharmaceuticals |
Deal Type | Going Private |
Deal Value | 95M USD |
Advisor(s) | Greenhill & Co., Inc. Jefferies (Financial) Sullivan & Cromwell Eubelius (Legal) |
SEARCH BY
Try For Free 7-Day Free Trial
Category | Company |
---|---|
Founded | 2007 |
Sector | Life Science |
Employees | 134 |
Revenue | 317M USD (2022) |
Eagle Pharmaceuticals is a pharmaceutical company focused on developing and commercializing injectable products that address the shortcomings, as identified by physicians, pharmacists and other stakeholders, of existing commercially successful injectable products. Eagle Pharmaceuticals was founded in 2007 and is based in Woodcliff Lake, New Jersey.
DEAL STATS | # |
---|---|
Overall | 2 of 3 |
Sector (Life Science) | 2 of 3 |
Type (Going Private) | 1 of 1 |
Country (United Kingdom) | 1 of 1 |
Year (2022) | 1 of 2 |
Size (of disclosed) | 1 of 2 |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2016-11-11 |
Arsia Therapeutics
Waltham, Massachusetts, United States Arsia Therapeutics, Inc. is a biopharmaceutical company based on a platform technology for protein formulation. Arsia produces high-concentration, low-viscosity drug products, enabling biologics that would otherwise be dosed by intravenous infusion to be administered by subcutaneous injection, or delivered by autoinjector pen or patch pump. |
Buy | $78M |
DATE | TARGET | DEAL TYPE | VALUE |
---|---|---|---|
2022-08-09 |
Enalare Therapeutics
Princeton, New Jersey, United States Enalare Therapeutics is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for patients suffering from life-threatening acute respiratory and critical care conditions, including community drug overdose, postoperative respiratory depression, and apnea of prematurity. Enalare Therapeutics is based in Princeton, New Jersey. |
Buy | - |